Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

drug licensing

Roche - Basel

Roche moves eye drug lampalizumab into phase III

It could be the first treatment for geographic atrophy

- PMLiVE

Avastin safe in eye disease, says Cochrane

Recommends off-label use of Roche drug as cheaper alternative to Novartis’ Lucentis

Roche - Basel

Roche wins early use RA approval for RoActemra in Europe

Adds to existing indications in arthritis and Castleman’s disease

- PMLiVE

Levinson resigns from Roche board

Declares conflict of interest due to his position as CEO at Calico

- PMLiVE

Diagnostics are rising up the pharma value chain

Pharma interview: Anssi Pulkkinen from Roche Diagnostics, Finland on the increasing prominence of diagnostics

Roche - Basel

Roche boosts respiratory presence with InterMune purchase

Deal is fourth takeover in three months for Swiss pharma company

- PMLiVE

Chugai soars on Roche buyout rumours

Reports circulating that Swiss company is poised to make $10bn offer

- PMLiVE

Avastin gets US green light for late-stage cervical cancer

Fifth oncology indication for Roche’s medicine

- PMLiVE

Roche blasts UK’s ‘broken’ HTA system as Kadcyla rejected

But NICE says it is 'very disappointed' with the company's pricing policy

- PMLiVE

Roche’s Avastin gets new EU nod in ovarian cancer

Wins new approval for hard-to-treat platinum-resistant recurrent form of disease

Roche Basel Switzerland

Roche pays $450m for ‘gene-silencing’ firm Santaris Pharma

Deal marks major return to the RNAi field it exited four years ago

Roche - Basel

Roche wins European approval for new leukaemia drug

Gazyvaro now available for use in treatment of blood cancer in the EU

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links